|0.237 -0.005 (-2.07%)||12-01 16:00|
|Targets||6-month :||0.35||1-year :||0.43|
|Resists||First :||0.3||Second :||0.37|
|Supports||First :||0.18||Second :||0.15|
|MAs||MA(5) :||0.24||MA(20) :||0.25|
|MA(100) :||0.45||MA(250) :||0.82|
|MACD||MACD :||-0.1||Signal :||-0.1|
|%K %D||K(14,3) :||32.9||D(3) :||26.2|
|52-week||High :||1.94||Low :||0.18|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ GNPX ] has closed above bottom band by 35.0%. Bollinger Bands are 70.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.
|If tomorrow:||Open lower||Open higher|
|High:||0.26 - 0.26||0.26 - 0.26|
|Low:||0.22 - 0.22||0.22 - 0.23|
|Close:||0.23 - 0.24||0.24 - 0.24|
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
Wed, 29 Nov 2023
Is Genprex Inc (GNPX) Stock a Bad Value? - InvestorsObserver
Fri, 17 Nov 2023
North American Morning Briefing: Stock Futures -2- - Morningstar
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
|Shares Out||59 (M)|
|Shares Float||59 (M)|
|Held by Insiders||2.3 (%)|
|Held by Institutions||15.8 (%)|
|Shares Short||1,640 (K)|
|Shares Short P.Month||1,650 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||0.2|
|Profit Margin||0 %|
|Operating Margin||0 %|
|Return on Assets (ttm)||-85 %|
|Return on Equity (ttm)||-158.1 %|
|Qtrly Rev. Growth||0 %|
|Gross Profit (p.s.)||0|
|Sales Per Share||0|
|Qtrly Earnings Growth||0 %|
|Operating Cash Flow||-24 (M)|
|Levered Free Cash Flow||-12 (M)|
|Price to Book value||1.12|
|Price to Sales||0|
|Price to Cash Flow||-0.58|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|